ES2902951T3 - Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas - Google Patents
Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas Download PDFInfo
- Publication number
- ES2902951T3 ES2902951T3 ES14800446T ES14800446T ES2902951T3 ES 2902951 T3 ES2902951 T3 ES 2902951T3 ES 14800446 T ES14800446 T ES 14800446T ES 14800446 T ES14800446 T ES 14800446T ES 2902951 T3 ES2902951 T3 ES 2902951T3
- Authority
- ES
- Spain
- Prior art keywords
- dexamethasone
- single unit
- dosage form
- triethyl citrate
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title claims abstract description 131
- 238000001356 surgical procedure Methods 0.000 title claims abstract description 61
- 206010036346 Posterior capsule opacification Diseases 0.000 title claims abstract description 33
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 26
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 26
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 122
- 239000000203 mixture Substances 0.000 claims abstract description 77
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims abstract description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 40
- 239000002552 dosage form Substances 0.000 claims abstract description 36
- 239000011780 sodium chloride Substances 0.000 claims abstract description 30
- 238000002347 injection Methods 0.000 claims abstract description 20
- 239000007924 injection Substances 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 238000007654 immersion Methods 0.000 claims abstract description 12
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims description 65
- 208000002177 Cataract Diseases 0.000 claims description 25
- 229940071643 prefilled syringe Drugs 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- 208000038016 acute inflammation Diseases 0.000 claims 2
- 230000006022 acute inflammation Effects 0.000 claims 2
- 239000003889 eye drop Substances 0.000 description 29
- 206010053781 Anterior chamber cell Diseases 0.000 description 20
- 229940012356 eye drops Drugs 0.000 description 20
- 210000002159 anterior chamber Anatomy 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 238000013268 sustained release Methods 0.000 description 13
- 239000012730 sustained-release form Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical class CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 150000001860 citric acid derivatives Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- -1 citric acid ester Chemical class 0.000 description 4
- 229960004875 difluprednate Drugs 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010054765 Anterior chamber inflammation Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940097575 durezol Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960003655 bromfenac Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940002946 acuvail Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940041504 bromday Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108010075600 citrate-binding transport protein Proteins 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940064811 ilevro Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940080267 lotemax Drugs 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229940083224 ozurdex Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013500 performance material Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940000493 prolensa Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827091P | 2013-05-24 | 2013-05-24 | |
| PCT/US2014/039319 WO2014190248A1 (en) | 2013-05-24 | 2014-05-23 | Use of sustained release dexamethasone in post-cataract surgery inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2902951T3 true ES2902951T3 (es) | 2022-03-30 |
Family
ID=51934201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14800446T Active ES2902951T3 (es) | 2013-05-24 | 2014-05-23 | Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10028965B2 (enExample) |
| EP (2) | EP3003318B1 (enExample) |
| JP (1) | JP6530744B2 (enExample) |
| KR (1) | KR102245354B1 (enExample) |
| CN (2) | CN105407896B (enExample) |
| AU (1) | AU2014268434B2 (enExample) |
| CA (1) | CA2913336C (enExample) |
| ES (1) | ES2902951T3 (enExample) |
| WO (1) | WO2014190248A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2726805T3 (es) | 2011-04-25 | 2019-10-09 | Icon Bioscience Inc | Guías de dosis para jeringa de inyección |
| EP4566638A3 (en) | 2015-05-29 | 2025-08-27 | Allergan, Inc. | Implant for treatment of an ocular condition |
| AU2017290143A1 (en) | 2016-06-30 | 2019-02-21 | Durect Corporation | Depot formulations |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| JP2020059652A (ja) * | 2016-12-26 | 2020-04-16 | 参天製薬株式会社 | タフルプロストとクエン酸エステルとを含有するデポ剤 |
| WO2019157198A2 (en) | 2018-02-09 | 2019-08-15 | Icon Bioscience, Inc. | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
| WO2020168106A1 (en) | 2019-02-13 | 2020-08-20 | Notable Labs, Inc. | Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer |
| IT201900003529A1 (it) * | 2019-03-11 | 2020-09-11 | Ntc S R L | Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| US11974979B2 (en) | 2022-01-29 | 2024-05-07 | Resurge Therapeutics, Inc. | Treatments for benign prostatic hyperplasia |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211793A (en) | 1979-03-19 | 1980-07-08 | American Cyanamid Company | Triethyl citrate solutions of PGE-type compounds |
| DE3500103C2 (de) | 1985-01-04 | 1987-01-22 | R.P. Scherer GmbH, 6930 Eberbach | Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff |
| US4889845A (en) | 1986-06-09 | 1989-12-26 | American Cyanamid Company | Vehicle for topical application of pharmaceuticals |
| WO1994010970A1 (en) | 1992-11-09 | 1994-05-26 | Quest International B.V. | Solubilizing agents |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| US20030216303A1 (en) | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| WO2002000137A1 (en) | 2000-06-28 | 2002-01-03 | Shukla Atul J | Biodegradable vehicles and delivery systems of biologically active substances |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6960346B2 (en) | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
| US20040253293A1 (en) | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| ITMI20032087A1 (it) | 2003-10-27 | 2005-04-28 | Pharmafilm S R L | Film autosupportanti per uso farmaceutico ed alimentare. |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| US8541413B2 (en) | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| EP1793803B1 (en) | 2004-10-01 | 2012-11-07 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
| EP2266638A3 (de) | 2009-06-25 | 2014-08-13 | Biotronik VI Patent AG | Biokorrodierbares Implantat mit einer aktiven Beschichtung |
| US20110160645A1 (en) | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
| ES2726805T3 (es) | 2011-04-25 | 2019-10-09 | Icon Bioscience Inc | Guías de dosis para jeringa de inyección |
| CA2838289C (en) * | 2011-06-10 | 2019-09-10 | Ramscor, Inc. | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
| AU2012325370A1 (en) | 2011-06-10 | 2014-01-30 | Ramscor, Inc. | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer |
| ES2908977T3 (es) | 2013-06-03 | 2022-05-04 | Mcneil Ab | Forma de dosificación farmacéutica sólida para liberar en la cavidad oral al menos dos ingredientes farmacéuticos activos |
-
2014
- 2014-05-23 JP JP2016515111A patent/JP6530744B2/ja active Active
- 2014-05-23 CA CA2913336A patent/CA2913336C/en active Active
- 2014-05-23 EP EP14800446.8A patent/EP3003318B1/en active Active
- 2014-05-23 ES ES14800446T patent/ES2902951T3/es active Active
- 2014-05-23 CN CN201480041856.1A patent/CN105407896B/zh active Active
- 2014-05-23 KR KR1020157036698A patent/KR102245354B1/ko active Active
- 2014-05-23 US US14/893,381 patent/US10028965B2/en active Active
- 2014-05-23 WO PCT/US2014/039319 patent/WO2014190248A1/en not_active Ceased
- 2014-05-23 AU AU2014268434A patent/AU2014268434B2/en active Active
- 2014-05-23 EP EP21215082.5A patent/EP4082525A1/en not_active Withdrawn
- 2014-05-23 CN CN201910639315.3A patent/CN110339153A/zh active Pending
-
2018
- 2018-06-26 US US16/018,931 patent/US10159683B2/en active Active
- 2018-12-10 US US16/215,579 patent/US20190105330A1/en not_active Abandoned
-
2022
- 2022-09-20 US US17/948,842 patent/US20230078906A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190105330A1 (en) | 2019-04-11 |
| WO2014190248A1 (en) | 2014-11-27 |
| JP6530744B2 (ja) | 2019-06-12 |
| US20180303851A1 (en) | 2018-10-25 |
| US10028965B2 (en) | 2018-07-24 |
| JP2016526039A (ja) | 2016-09-01 |
| AU2014268434B2 (en) | 2018-11-22 |
| EP3003318B1 (en) | 2021-12-22 |
| AU2014268434A1 (en) | 2015-12-10 |
| CN105407896B (zh) | 2019-08-27 |
| US20160120879A1 (en) | 2016-05-05 |
| CN105407896A (zh) | 2016-03-16 |
| US10159683B2 (en) | 2018-12-25 |
| CN110339153A (zh) | 2019-10-18 |
| EP4082525A1 (en) | 2022-11-02 |
| CA2913336C (en) | 2020-12-15 |
| KR20160040471A (ko) | 2016-04-14 |
| EP3003318A1 (en) | 2016-04-13 |
| CA2913336A1 (en) | 2014-11-27 |
| US20230078906A1 (en) | 2023-03-16 |
| EP3003318A4 (en) | 2017-01-04 |
| KR102245354B1 (ko) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2902951T3 (es) | Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas | |
| US11439590B2 (en) | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| JP2020063236A (ja) | 後眼部障害を処置するための方法およびデバイス | |
| US11510916B2 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| JP2019501200A (ja) | 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス | |
| KR20200000487A (ko) | 주사용의 안정한 보존제-비함유 산동 및 항-염증 용액 | |
| AU2003279055A1 (en) | Methods for treatment and/or prevention of retinal disease | |
| JP2021121608A (ja) | 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物 | |
| US20160175323A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| US20160243031A1 (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| TW202400215A (zh) | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 | |
| AU2017260327B2 (en) | Pharmaceutical Ophthalmic compositions and methods for fabricating thereof | |
| US20190105320A1 (en) | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof | |
| US20190111045A1 (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| JP2023179508A (ja) | 眼感染症を予防するための抗生物質溶液および注射方法 | |
| HK40008204A (en) | Dexamethasone unit dosage form, kit and use for post-cataract surgery inflammation | |
| US9814673B2 (en) | Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof |